Archives
-
Optimized hiPSC Differentiation for Functional Platelets
2026-08-20
Yue et al. developed an optimized embryoid body-based protocol that improves megakaryocyte production and functional platelet release from human induced pluripotent stem cells. The strategy combines higher starting cell input, human platelet lysate, cytokine-replacing small molecules, and maturation-promoting compounds to shorten production time, increase yield, and reduce cost.
-
EdU Imaging Kits (Cy5) in Wound-Healing Biology
2026-08-20
EdU Imaging Kits (Cy5) provide a morphology-preserving way to measure DNA synthesis in epithelial wound models. This article translates recent DCPS findings in diabetic foot ulcers into practical imaging and flow-cytometry assay decisions.
-
Tauroursodeoxycholic Acid: ER Stress Workflows
2026-08-19
Tauroursodeoxycholic Acid provides a practical chemical-chaperone strategy for connecting ER stress, mitochondrial instability, inflammation, and apoptosis in cell and tissue models. This workflow-focused guide shows how to position TUDCA as a pharmacological comparator in neuroinflammation studies while extending its use to metabolic and regenerative research.
-
Lumiracoxib and the Timing of COX-2 Biology
2026-08-19
A translational framework for using Lumiracoxib to distinguish protective from maladaptive COX-2 signaling in muscle injury, with emphasis on temporal design, vascular readouts, assay controls, and research-grade compound handling.
-
Telmisartan in Cardiac Hypertrophy Research
2026-08-18
Telmisartan provides an AT1-receptor-centered control for Ang II cardiac hypertrophy models, helping researchers distinguish upstream receptor blockade from downstream RIP3/CaMKII regulation. This guide covers DMSO preparation, assay design, pathway readouts, comparative use with isochlorogenic acid A, and troubleshooting for reproducible cardiovascular disease research.
-
High-Throughput Measurement of Fractional Killing
2026-08-18
Inde, Rodencal, and Dixon present a high-throughput microscopy protocol for measuring drug-induced fractional killing over time rather than relying on a single bulk viability endpoint. The workflow combines nuclear fluorescent labeling of live cells with dead-cell imaging, enabling parallel comparison of hundreds of treatment conditions and analysis of variable responses to MEK1/2 inhibitors.
-
EZ Cap™ Cas9 mRNA (m1Ψ) for Precise Editing
2026-08-17
Build transient CRISPR workflows around Cap1-capped, m1Ψ-modified Cas9 mRNA for efficient genome editing in mammalian cells. This practical guide connects RNA handling, dose optimization, nuclear-export biology, and troubleshooting to improve reproducibility without overstating product-specific performance.
-
MOG (35-55) for Reproducible EAE Research
2026-08-17
Build more consistent experimental autoimmune encephalomyelitis models with a defined myelin oligodendrocyte glycoprotein peptide and a workflow that connects disease scoring to mechanistic neuroinflammation assays. This guide translates the latest PARP7–STAT1/STAT2 findings into practical choices for multiple sclerosis research, dose selection, sample handling, and troubleshooting.
-
TH287: Turning Oxidative Stress Into Radiosensitivity
2026-08-16
A translational analysis of TH287 as an MTH1 inhibitor for cancer research, focusing on oxidized nucleotide sanitization, radiation scheduling, DNA damage biology, and the evidence needed to move from cell-based radiosensitization to a credible therapeutic hypothesis.
-
PARP7–STAT1/2 Control of EAE
2026-08-15
A 2025 Cell Reports study identifies PARP7 as a suppressor of type I interferon signaling rather than interferon production. By linking STAT1/STAT2 mono-ADP-ribosylation to ubiquitination and p62-dependent autophagic degradation, the work provides a mechanistic explanation for why PARP7 inhibition alleviates experimental autoimmune encephalomyelitis in mice.
-
Protoporphyrin IX at the Heme-Ferroptosis Interface
2026-08-14
Protoporphyrin IX is more than a heme precursor: it is a photodynamic compound and a powerful experimental lens for studying iron-dependent biology. This article connects its chemistry to ferroptosis assay design while clarifying what recent hepatocellular carcinoma evidence does—and does not—demonstrate.
-
Autophagy–Liver Metastasis Signature in CRC
2026-08-14
Bai et al. integrated bulk and single-cell transcriptomic evidence to develop a six-gene prognostic signature linking autophagy, liver metastasis, and immune suppression in colorectal cancer. The model improved risk stratification and associated high-risk disease with TIDE-predicted immunotherapy resistance, macrophage polarization, and CD8+ T-cell exhaustion.
-
Mouse Tissue Lysis Kit (K1038) Workflow Guide
2026-08-13
The Mouse Tissue Lysis Kit (K1038) prepares lysates from mouse tail, toe, or ear tissue for direct PCR-based genotyping without a separate DNA extraction or purification step. It is intended for scientific research, including molecular biology workflows, and must not be used for diagnostic or medical applications.
-
Patient-Derived Gastric Cancer Assembloids
2026-08-13
The reference study develops gastric cancer assembloids by combining patient-matched tumor organoids with separately expanded stromal subpopulations. Its results show that stromal composition reshapes gene expression and drug sensitivity, making the model useful for studying tumor–stroma interactions, resistance, and personalized treatment responses.
-
CAMLs as Blood Biomarkers of Cancer Progression
2026-08-12
The reference study positions circulating cancer-associated macrophage-like cells (CAMLs), a blood-borne form of phagocytic polyploid giant cancer cells, as clinically informative markers of progression across multiple solid tumors. Its prospective, multi-institutional design combines clinical correlation with cellular phenotyping, while also clarifying that CAMLs may reflect metastatic-niche biology rather than simply passive tumor debris.